Efficacy of Xihuang capsules combined with albumin-bound paclitaxel in the third-line and beyond treatment of advanced non-small cell lung cancer and its impact on tumor biomarkers
MA Ming-ying
KANG Yi-xin
WANG Jun-qi
ZHANG Zhi-ye
Abstract：Objective To analyze the efficacy of Xihuang capsule combined with albumin bound paclitaxel in the treatment of advanced non-small cell lung cancer(NSCLC)patients and its impact on tumor markers.Methods Sixty confirmed advanced NSCLC patients,who willing to undergo treatment between March 2020 and September 2021,were se-lected as the study subjects.Among them,30 patients treated with albumin-bound paclitaxel were allocated to the control group,while the other 30 patients treated with a combination of Xihuang capsules and albumin-bound paclitaxel constitu-ted the study group.The two groups were compared for objective response rate(ORR),disease control rate(DCR),me-dian progression-free survival(mPFS),and overall survival(OS).Serum tumor biomarkers including carbohydrate an-tigen 125(CA125),carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),and cytokeratin fragment 21-1(CYFRA 21-1)were analyzed for changes.Adverse reactions during treatment were also observed.Results In the study group,the ORR was 36.67％,DCR was 76.67％,mPFS was(6.35±2.02)months,and OS was(9.77± 3.13)months.In the control group,the ORR was 13.33％,DCR was 50.00％,mPFS was(3.11±0.94)months,and OS was(5.79±1.98)months.Significant differences were observed between the two groups in terms of ORR,DCR,mPFS,and OS(P＜0.05).After treatment,significant reductions were noted in serum levels of CA125[(51.34± 14.72)U/mLvs.(75.63±18.41)U/mL,t=5.644,P=0.000],CEA[(19.73±3.68)ng/mL vs.(24.51± 5.22)ng/mL,t=4.099,P=0.000],CA199[(21.33±3.14)U/mL vs.(24.38±4.15)U/mL,t=3.210,P=0.002],and CYFRA 21-1[(2.46±0.37)ng/mL vs.(3.22±0.78)ng/mL,t=21.787,P=0.000]in the study group compared to the control group(P＜0.05).Additionally,the study group had a higher incidence of capillary prolif-eration and hypothyroidism(P＜0.05),lower incidence of hematologic and gastrointestinal toxicity(P＜0.05),and comparable incidence of hair loss,neurological impairment,hepatic and renal toxicity,and fever(P＞0.05)compared to the control group.Conclusion Xihuang capsules combined with albumin-bound paclitaxel as a third-line and beyond treatment for advanced NSCLC patients shows superior short-term and long-term efficacy.It significantly lowers serum tumor biomarker levels,delays tumor progression,and exhibits a favorable safety profile with minimal toxicity.
Keywords：Xihuang capsulesalbumin bound paclitaxelnon-small cell lung cancerclinical efficacytumor markers
Publication Date：2023-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 1536-1541 )